Paratiroid Bezi ve Kas İskelet Sistem Hastalıkları
Özet
Paratiroid bezi tarafından salgılanan parathormon (PTH), kalsiyum ve fosfor metabolizmasını dengeleyerek kemik, böbrek ve gastrointestinal sistem üzerinde hayati işlevler görür. Bu hormonun sentezindeki anormallikler kas-iskelet sisteminde geniş bir hastalık spektrumuna yol açar. Hiperparatiroidizm, çoğunlukla paratiroid adenomuna bağlı gelişen, kemik rezorbsiyonu (osteoitis fibroza sistika), Brown tümörleri, kortikal kemik kaybına bağlı osteoporoz ve artmış kırık riski ile karakterize bir tablodur. Ayrıca kalsiyum pirofosfat dihidrat (CPPD) ve monosodyum ürat kristallerinin birikmesiyle pseudogut ve gut gibi kristal artropatilere, kolajenaz aktivitesinin artmasıyla tendon rüptürlerine ve proksimal kas güçsüzlüklerine neden olur. Hipoparatiroidizm ise genellikle cerrahi hasar sonucu gelişen PTH eksikliğiyle ortaya çıkar; düşük kemik döngüsü nedeniyle kemik kütlesinde artış, nöromuskuler hiperirritabiliteye bağlı tetani, kas spazmları (Chvostek ve Trousseau bulguları) ve kronik dönemde yumuşak doku kalsifikasyonları ile seyreder. Son olarak, PTH'ye hedef organ yanıtsızlığı ile karakterize pseudohipoparatiroidizm, obezite, kısa boy ve metakarpal kısalık gibi bulgularla ayrışır.
Parathyroid hormone (PTH), secreted by the parathyroid gland, plays a vital role in balancing calcium and phosphorus metabolism, acting directly on bones, kidneys, and the gastrointestinal tract. Abnormalities in PTH synthesis lead to a broad spectrum of musculoskeletal disorders. Hyperparathyroidism, mostly arising from parathyroid adenomas, is characterized by bone resorption (osteitis fibrosa cystica), Brown tumors, cortical bone loss leading to osteoporosis, and an increased risk of fractures. It also causes crystal arthropathies such as pseudogout and gout due to calcium pyrophosphate dihydrate (CPPD) and monosodium urate depositions, tendon ruptures driven by increased collagenase activity, and proximal muscle weakness. Conversely, hypoparathyroidism, typically caused by surgical trauma, manifests as a deficiency in PTH; it features increased bone mass due to low bone turnover, neuromuscular hyperirritability presenting as tetany and muscle spasms (Chvostek and Trousseau signs), and soft tissue calcifications in the chronic stage. Lastly, pseudohypoparathyroidism, characterized by target organ resistance to PTH, is distinguished by specific clinical features including obesity, short stature, and shortened metacarpal bones.
Referanslar
Khan M, Jose A, Sharma S. Physiology, Parathyroid Hormone. StatPearls. Treasure Island (FL)2022.
Lofrese JJ, Basit H, Lappin SL. Physiology, Parathyroid. StatPearls. Treasure Island (FL)2022.
Pappu R, Jabbour SA, Reginato AM, Reginato AJ. Musculoskeletal manifestations of primary hyperparathyroidism. Clin Rheumatol. 2016;35(12):3081-7.
Naji Rad S, Deluxe L. Osteitis Fibrosa Cystica. StatPearls. Treasure Island (FL)2022.
Kalapala L, Keerthi Sai S, Babburi S, Venigalla A, Pinisetti S, Kotti AB, et al. An Endocrine Jaw Lesion: Dentist Perspective in Diagnosis. Case Rep Dent. 2016;2016:2582038.
Mirza F, Canalis E. Management of endocrine disease: Secondary osteoporosis: pathophysiology and management. Eur J Endocrinol. 2015;173(3):R131-51.
Bandeira F, Cusano NE, Silva BC, Cassibba S, Almeida CB, Machado VC, et al. Bone disease in primary hyperparathyroidism. Arq Bras Endocrinol Metabol. 2014;58(5):553-61.
Khosla S, Melton LJ, 3rd, Wermers RA, Crowson CS, O'Fallon W, Riggs B. Primary hyperparathyroidism and the risk of fracture: a population-based study. J Bone Miner Res. 1999;14(10):1700-7.
Khan A, Grey A, Shoback D. Medical management of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab. 2009;94(2):373-81.
Camozzi V, Luisetto G, Basso SM, Cappelletti P, Tozzoli R, Lumachi F. Treatment of chronic hypercalcemia. Med Chem. 2012;8(4):556-63.
Rosales-Alexander JL, Balsalobre Aznar J, Magro-Checa C. Calcium pyrophosphate crystal deposition disease: diagnosis and treatment. Open Access Rheumatol. 2014;6:39-47.
Bencardino JT, Hassankhani A. Calcium pyrophosphate dihydrate crystal deposition disease. Semin Musculoskelet Radiol. 2003;7(3):175-85.
Abhishek A. Calcium pyrophosphate deposition disease: a review of epidemiologic findings. Curr Opin Rheumatol. 2016;28(2):133-9.
Zamora EA, Naik R. Calcium Pyrophosphate Deposition Disease. StatPearls. Treasure Island (FL)2022.
Zhang W, Doherty M, Bardin T, Barskova V, Guerne PA, Jansen TL, et al. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. Ann Rheum Dis. 2011;70(4):563-70.
Hainer BL, Matheson E, Wilkes RT. Diagnosis, treatment, and prevention of gout. Am Fam Physician. 2014;90(12):831-6.
Hisatome I, Ishimura M, Sasaki N, Yamakawa M, Kosaka H, Tanaka Y, et al. Renal handling of urate in two patients with hyperuricemia and primary hyperparathyroidism. Intern Med. 1992;31(6):807-11.
Mintz DH, Canary JJ, Carreon G, Kyle LH. Hyperuricemia in hyperparathyroidism. N Engl J Med. 1961;265:112-5.
Hui JY, Choi JW, Mount DB, Zhu Y, Zhang Y, Choi HK. The independent association between parathyroid hormone levels and hyperuricemia: a national population study. Arthritis Res Ther. 2012;14(2):R56.
Shiota E, Tsuchiya K, Yamaoka K, Kawano O. Spontaneous major tendon ruptures in patients receiving long-term hemodialysis. Clin Orthop Relat Res. 2002(394):236-42.
Ruiz J, Rios A, Rodriguez JM, Llorente S. Spontaneous tendon ruptures in chronic renal failure. Nefrologia. 2017;37(3):341-3.
Katzberg HD, Kassardjian CD. Toxic and Endocrine Myopathies. Continuum (Minneap Minn). 2016;22(6, Muscle and Neuromuscular Junction Disorders):1815-28.
Bilezikian JP. Hypoparathyroidism. J Clin Endocrinol Metab. 2020;105(6).
Shoback D. Clinical practice. Hypoparathyroidism. N Engl J Med. 2008;359(4):391-403.
Heino M, Peterson P, Kudoh J, Nagamine K, Lagerstedt A, Ovod V, et al. Autoimmune regulator is expressed in the cells regulating immune tolerance in thymus medulla. Biochem Biophys Res Commun. 1999;257(3):821-5.
Vetter T, Lohse MJ. Magnesium and the parathyroid. Curr Opin Nephrol Hypertens. 2002;11(4):403-10.
Touliatos JS, Sebes JI, Hinton A, McCommon D, Karas JG, Palmieri GM. Hypoparathyroidism counteracts risk factors for osteoporosis. Am J Med Sci. 1995;310(2):56-60.
Rubin MR. Skeletal Manifestations of Hypoparathyroidism. Endocrinol Metab Clin North Am. 2018;47(4):825-37.
Kruse K, Kracht U, Wohlfart K, Kruse U. Biochemical markers of bone turnover, intact serum parathyroid horn and renal calcium excretion in patients with pseudohypoparathyroidism and hypoparathyroidism before and during vitamin D treatment. Eur J Pediatr. 1989;148(6):535-9.
Cusano NE, Nishiyama KK, Zhang C, Rubin MR, Boutroy S, McMahon DJ, et al. Noninvasive Assessment of Skeletal Microstructure and Estimated Bone Strength in Hypoparathyroidism. J Bone Miner Res. 2016;31(2):308-16.
Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L. Postsurgical hypoparathyroidism--risk of fractures, psychiatric diseases, cancer, cataract, and infections. J Bone Miner Res. 2014;29(11):2504-10.
Mitchell DM, Regan S, Cooley MR, Lauter KB, Vrla MC, Becker CB, et al. Long-term follow-up of patients with hypoparathyroidism. J Clin Endocrinol Metab. 2012;97(12):4507-14.
Chawla H, Saha S, Kandasamy D, Sharma R, Sreenivas V, Goswami R. Vertebral Fractures and Bone Mineral Density in Patients With Idiopathic Hypoparathyroidism on Long-Term Follow-Up. J Clin Endocrinol Metab. 2017;102(1):251-8.
Han P, Trinidad BJ, Shi J. Hypocalcemia-induced seizure: demystifying the calcium paradox. ASN Neuro. 2015;7(2).
Goswami R, Sharma R, Sreenivas V, Gupta N, Ganapathy A, Das S. Prevalence and progression of basal ganglia calcification and its pathogenic mechanism in patients with idiopathic hypoparathyroidism. Clin Endocrinol (Oxf). 2012;77(2):200-6.
Goswami R, Ray D, Sharma R, Tomar N, Gupta R, Gupta N, et al. Presence of spondyloarthropathy and its clinical profile in patients with hypoparathyroidism. Clin Endocrinol (Oxf). 2008;68(2):258-63.
Mannstadt M, Bilezikian JP, Thakker RV, Hannan FM, Clarke BL, Rejnmark L, et al. Hypoparathyroidism. Nat Rev Dis Primers. 2017;3:17055.
Policepatil SM, Caplan RH, Dolan M. Hypocalcemic myopathy secondary to hypoparathyroidism. WMJ. 2012;111(4):173-5.
Dai CL, Sun ZJ, Zhang X, Qiu MC. Elevated muscle enzymes and muscle biopsy in idiopathic hypoparathyroidism patients. J Endocrinol Invest. 2012;35(3):286-9.
Mantovani G. Clinical review: Pseudohypoparathyroidism: diagnosis and treatment. J Clin Endocrinol Metab. 2011;96(10):3020-30.
